PRESS RELEASE

Dipharma Francis S.r.l. completes acquisition of Kalexsyn, Inc.

Milan, Italy – Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.

Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all of the issued and outstanding shares of Kalexsyn through its American subsidiary Dipharma, Inc.

Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and provides chemistry services that support the drug discovery and development activities of their customers.

About Dipharma Francis S.r.l.
With revenues exceeding USD 125 million, Dipharma is one of the leading family-owned European manufacturers of Active Pharmaceutical Ingredients. Its three manufacturing sites located in northern Italy have been successfully inspected by the major health authorities since 1970. The Company develops innovative chemical processes and crystalline forms for the most renowned pharmaceutical companies in USA, Europe, Japan, and other regions of the globe. Its manufacturing facilities supply from laboratory to industrial quantities whilst complying fully with the most stringent quality standards.

About Kalexsyn, Inc.
Kalexsyn is a world-class chemistry CRO, whose scientists average 15 years’ experience in hit validation, lead optimization and solving tough synthetic problems. It provides stable label synthesis, custom synthesis, process impurity synthesis, and process route development to its world-wide clients. Kalexsyn offers an outstanding CRO experience with fixed quote as well as short and long-term FTE arrangements. The Company has research laboratories in Kalamazoo, Michigan.

For more information:

Paola Clerici
Communication Manager
Dipharma Francis S.r.l.
Tel. +39 0238228320
paola.clerici@dipharma.com
www.dipharma.com